Cardiovasc Saf Trials all New Diabetes Mellitus Drugs
A double-blind, randomized phase 2 study comparing various doses (1, 5, 10, 15 mg) of once weekly tirzepatide, dulaglutide (1.5 mg) and placebo, in patients with T2DM, showed tirzepatide was superior on weight loss and glucose-lowering compared to both dulaglutide and placebo [52]
For patients with Wilsons disease or suspected Wilsons disease, any copper-containing therapy is contraindicated
reported that H5N1 IAV infection in lung epithelial cells (A549 cells) decreased Cu/Zn superoxide dismutase (SOD1) expression, which could enhance ROS production, viral replication, and the inflammatory response 27
Combined with the drug, these beneficial results were consistently observed across all tested glycating and oxidizing agents (Figs